The down-regulation of Lp-PLA2 expression inhibits the JAK2/STAT3 signaling pathway, reduces lipid accumulation, promotes autophagy, suppresses the production of inflammatory factors, and delays the progression of NAFLD. Here, STAT3 is linked to metabolic dysfunction-associated steatotic liver disease.